NASDAQ:EGRX - Eagle Pharmaceuticals Stock Price, Forecast & News

Eagle Pharmaceuticals trades on the NASDAQ under the ticker symbol "EGRX."

Eagle Pharmaceuticals Inc (NASDAQ:EGRX) posted its quarterly earnings data on Tuesday, November, 12th. The specialty pharmaceutical company reported $0.26 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.43 by $0.17. The specialty pharmaceutical company earned $41.10 million during the quarter, compared to analyst estimates of $45.44 million. Eagle Pharmaceuticals had a return on equity of 16.07% and a net margin of 12.72%. The company's quarterly revenue was down 19.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.18 earnings per share. View Eagle Pharmaceuticals' Earnings History.

Eagle Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Eagle Pharmaceuticals.

3 equities research analysts have issued 12-month price targets for Eagle Pharmaceuticals' stock. Their forecasts range from $50.00 to $66.00. On average, they anticipate Eagle Pharmaceuticals' share price to reach $58.00 in the next twelve months. This suggests a possible upside of 10.0% from the stock's current price. View Analyst Price Targets for Eagle Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eagle Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Eagle Pharmaceuticals.

News headlines about EGRX stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Eagle Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Eagle Pharmaceuticals.

Some companies that are related to Eagle Pharmaceuticals include Deciphera Pharmaceuticals (DCPH), Alkermes (ALKS), Amicus Therapeutics (FOLD), Taro Pharmaceutical Industries (TARO), ChemoCentryx (CCXI), Uniqure (QURE), Insmed (INSM), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN), Karuna Therapeutics (KRTX), Epizyme (EPZM), Ra Pharmaceuticals (RARX), Synthorx (THOR) and Turning Point Therapeutics (TPTX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eagle Pharmaceuticals investors own include Gilead Sciences (GILD), Exelixis (EXEL), Teekay Tankers (TNK), Celgene (CELG), Intercept Pharmaceuticals (ICPT), AbbVie (ABBV), GW Pharmaceuticals PLC- (GWPH), bluebird bio (BLUE), Radius Health (RDUS) and Clovis Oncology (CLVS).

Eagle Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include State Street Corp (4.47%), LSV Asset Management (2.70%), Credit Suisse AG (1.77%), Chartwell Investment Partners LLC (1.38%), AJO LP (1.23%) and Renaissance Technologies LLC (1.15%). Company insiders that own Eagle Pharmaceuticals stock include Douglas L Braunstein, Hudson Executive Capital Lp, Sander A Flaum and Scott Tarriff. View Institutional Ownership Trends for Eagle Pharmaceuticals.

EGRX stock was sold by a variety of institutional investors in the last quarter, including LSV Asset Management, Bank of America Corp DE, FMR LLC, Connor Clark & Lunn Investment Management Ltd., Chicago Equity Partners LLC, Oxford Asset Management LLP, UBS Group AG and PNC Financial Services Group Inc.. Company insiders that have sold Eagle Pharmaceuticals company stock in the last year include Douglas L Braunstein, Hudson Executive Capital Lp and Scott Tarriff. View Insider Buying and Selling for Eagle Pharmaceuticals.

EGRX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., State Street Corp, California Public Employees Retirement System, Schroder Investment Management Group, Martingale Asset Management L P, Prudential Financial Inc. and Seizert Capital Partners LLC. View Insider Buying and Selling for Eagle Pharmaceuticals.

Shares of EGRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EGRX stock can currently be purchased for approximately $52.71.

Eagle Pharmaceuticals has a market capitalization of $720.55 million and generates $213.31 million in revenue each year. The specialty pharmaceutical company earns $31.90 million in net income (profit) each year or $2.09 on an earnings per share basis. Eagle Pharmaceuticals employs 96 workers across the globe.View Additional Information About Eagle Pharmaceuticals.

The official website for Eagle Pharmaceuticals is http://www.eagleus.com/.

Eagle Pharmaceuticals' mailing address is 50 TICE BOULEVARD SUITE 315, WOODCLIFF LAKE NJ, 07677. The specialty pharmaceutical company can be reached via phone at 201-326-5300 or via email at [email protected]